ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMDespesas comerciais, gerais e administrativas1.88 B1.69 B1.69 B1.72 B1.95 B1.6 B6.96 BPesquisa e desenvolvimento1.72 B1.49 B1.74 B1.9 B2.14 B1.72 B7.5 BLucro operacional2.31 B1.18 B2.66 B2.53 B2.72 B2.67 B10.57 BLucro não operacional, total-782 M1.52 B-394 M2.08 B-553 M75 M1.21 BDespesa com juros, líquida de juros capitalizados747 M723 M694 M685 M653 M657 M2.69 BReceitas não operacionais, líquidas das despesas com juros-782 M1.52 B-1.09 B1.4 B-1.21 B-582 M-1.48 BReceitas/despesas incomuns———————Lucro antes dos impostos781 M1.97 B1.57 B3.92 B8.98 B2.08 B16.55 BParticipação no lucro-1 M——————Impostos155 M243 M136 M705 M181 M265 M1.29 BParticipação de minoritários———————Outras receitas/despesas após impostos-131 M50 M23 M28 M-250 M67 M-132 MLucro líquido antes das operações descontinuadas627 M1.73 B1.43 B3.22 B1.33 B1.82 B7.8 BOperações descontinuadas———————Lucro líquido627 M1.73 B1.43 B3.22 B1.33 B1.82 B7.8 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas627 M1.73 B1.43 B3.22 B1.33 B1.82 B7.8 BLucro básico por ação1.173.222.665.982.473.3714.48Lucro diluído por ação1.173.22.655.932.453.3414.37Número médio de ações básicas537 M538 M538 M538 M538 M540 M—Ações diluídas541 M541 M541 M542 M542 M544 M—EBITDA3.71 B2.56 B4 B3.83 B3.85 B3.78 B15.46 BEBIT2.31 B1.18 B2.66 B2.53 B2.72 B2.67 B10.57 BCusto da receita3.11 B2.97 B3.01 B3.08 B2.98 B2.74 B11.81 BOutros componentes do custo———————Amortização e depreciação (fluxo de caixa)1.4 B1.39 B1.34 B1.31 B1.13 B1.12 B4.9 B
Amgen Inc. - Common Stock
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.